Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Relapsed Non Hodgkin Lymphoma Clinical Trial

Official title:

Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01811368
• Other study ID #: 367905
• Secondary ID: UCDCC#233NCI-201
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 12, 2013
• Est. completion date: December 2023

Study information

• Verified date: November 2022
• Source: University of California, Davis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving rituximab, antithymocyte globulin, and TLI before the transplant together with cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Giving a radiolabeled monoclonal antibody before a donor peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin lymphoma.

Description:

PRIMARY OBJECTIVES:

I. To measure the response conversion (progressive disease [PD]/stable disease [SD] to partial response [PR] and complete response [CR]).

SECONDARY OBJECTIVES:

I. To assess the time to engraftment/chimerism. II. To assess the rate of acute and chronic graft-versus-host disease (GVHD). III. To assess toxicity. IV. To determine the overall survival. V. To investigate immune functional and phenotypic analysis. VI. To measure two year event free survival (EFS).

OUTLINE:

CONDITIONING REGIMEN: Patients receive rituximab intravenously (IV) on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.

TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) on day 0.

GVHD PROPHYLAXIS: Patients receive cyclosporine orally (PO) twice daily (BID) or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28.

After completion of study treatment, patients are followed up periodically.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: December 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed relapsed cluster of differentiation (CD)20+ non-Hodgkin's lymphoma (NHL) (included in this category are follicular grade I, II, III, marginal zone, mantle cell, diffuse large B cell, small lymphocytic lymphoma) and CD20+ Hodgkin's disease for which standard curative therapy does not exist or is no longer effective

• Patients must have had at least one prior chemotherapeutic regimen; steroids alone and local radiation do not count as regimens; radiotherapy must have been completed at least 4 weeks prior to entry into the study; Rituxan alone does not count as a regimen; however, Bexxar or Zevalin (ibritumomab tiuxetan) do and patients must have completed radioimmunotherapy (RIT) > 12 months prior to enrollment

• Karnofsky performance status of = 60%

• Life expectancy of greater than 3 months

• Total bilirubin within institutional normal limits

• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 times institutional upper limit of normal

• Creatinine within normal institutional limits OR creatinine clearance >= 60 ml/min/1.73 m^2 for patients with creatinine levels above institutional normal

• Blood counts no restrictions

• Patients who had anything less than a CR (PR, SD or progressive disease) to their last salvage regimen

• Ability to understand and the willingness to sign a written informed consent document

• Patients fit for non-myeloablative transplantation or best treatment that have an available matched (9/10 or better) related or unrelated donor

• Patients who are considered rituximab refractory (defined as progression within 6 months of their last rituximab-containing regimen)

Exclusion Criteria:

• Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study, rituximab within three months (unless there is evidence of progression), or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excluded; this does not include the use of steroids which may continue until two days prior to enrollment

• Patients may not be receiving any other investigational agents

• Failure to obtain insurance/payment authorization for Zevalin, unless the subject agrees to cover the cost

• Patients with known active brain metastases, other neurological disorders/dysfunction or a history of seizure disorder, or other neurological dysfunction should be excluded from this clinical trial because of their poor prognosis

• Patients who have an uncontrolled infection (presumed or documented) with progression after appropriate therapy for greater than one month

• Patients with symptomatic coronary artery disease, uncontrolled congestive heart failure; left ventricular ejection fraction is not required to be measured, however if it is measured, patient is excluded if ejection fraction is < 30%

• Patients requiring supplementary continuous oxygen; diffusion capacity of the lung of carbon monoxide (DLCO) is not required to be measured, however if it is measured, patient is excluded if DLCO < 35%

• Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function and histology, and for the degree of portal hypertension

• Patients with any of the following liver function abnormalities will be excluded:

• Fulminant liver failure

• Cirrhosis with evidence of portal hypertension or bridging fibrosis

• Alcoholic hepatitis

• Esophageal varices

• A history of bleeding esophageal varices

• Hepatic encephalopathy

• Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time

• Ascites related to portal hypertension

• Chronic viral hepatitis with total serum bilirubin > 3 mg/dL

• Symptomatic biliary disease

• Pregnant women are excluded from this study

• Human immunodeficiency virus (HIV)-positive patients

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Refractory Non Hodgkin Lymphoma
• Relapsed Non Hodgkin Lymphoma

Intervention

Biological:
• rituximab
Given IV
• ibritumomab tiuxetan
Given IV
• anti-thymocyte globulin
Given IV

Radiation:
• total nodal irradiation
Undergo TLI

Procedure:
• peripheral blood stem cell transplantation
Undergo allogeneic peripheral blood stem cell transplant
• allogeneic hematopoietic stem cell transplantation
Undergo allogeneic peripheral blood stem cell transplant

Drug:
• cyclosporine
Given PO or IV
• mycophenolate mofetil
Given PO or IV

Locations

Country	Name	City	State
United States	University of California Davis	Sacramento	California

Sponsors (2)

Lead Sponsor	Collaborator
Joseph Tuscano	Spectrum Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response conversion rate (PD/SD to PR and CR)	Calculated along with 95% confidence intervals (CI). Logistic regression will be used to assess the impact of patient characteristics (e.g., low/high lactate dehydrogenase isoenzyme-3 [LDH] or immunologic correlates) on the response conversion rate.	Up to 60 days post-transplant
Secondary	Time to engraftment/chimerism	Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.	Up to 3 years
Secondary	Rate of acute GVHD		Up to day 730
Secondary	Rate of chronic GVHD		Up to day 730
Secondary	Overall survival	Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.	Up to day 730
Secondary	EFS	Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.	2 years
Secondary	Toxicities	Toxicities as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v4.0	Up to day 730